![A Landmark Year for Apomorphine – Advancing Parkinson's Disease Management with New Clinical Evidence - touchNEUROLOGY A Landmark Year for Apomorphine – Advancing Parkinson's Disease Management with New Clinical Evidence - touchNEUROLOGY](https://www.touchneurology.com/wp-content/uploads/sites/3/2017/10/Figure_1_The_history_of_apomorphine.png)
A Landmark Year for Apomorphine – Advancing Parkinson's Disease Management with New Clinical Evidence - touchNEUROLOGY
Package Leaflet: Information for the user APO-go® PEN 10 mg/ml Solution for Injection * Apomorphine hydrochloride * Abbreviated
W Communication Agency - MORE ON-TIME WITH APO-GO® APO-go PEN CAMPAIGN When Grünenthal launched APO-go pen, a treatment of Parkinson's disease, they needed urgent help – a complete product launch package adapted
![A Landmark Year for Apomorphine – Advancing Parkinson's Disease Management with New Clinical Evidence - touchNEUROLOGY A Landmark Year for Apomorphine – Advancing Parkinson's Disease Management with New Clinical Evidence - touchNEUROLOGY](https://www.touchneurology.com/wp-content/uploads/sites/3/2017/10/Figure_3_Patient_case_study_-a-personalised_approach_to.png)